Efficient uptake of recombinant α-galactosidase a produced with a gene-manipulated yeast by fabry mice kidneys

Molecular Medicine

Volumn 18, Issue 1, 2012, Pages 76-82

  Tsukimura, Takahiro ^a   Kawashima, Ikuo ^a,b   Togawa, Tadayasu ^a   Kodama, Takashi ^a   Suzuki, Toshihiro ^a   Watanabe, Toru ^c   Chiba, Yasunori ^a,c   Jigami, Yoshifumi ^c   Fukushige, Tomoko ^d   Kanekura, Takuro ^d   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,6 MANNOSYLTRANSFERASE; GLYCAN; GLYCOPROTEIN; GLYCOSPHINGOLIPID; MANNOSYLTRANSFERASE; RECOMBINANT ALPHA GALACTOSIDASE A; RECOMBINANT ENZYME; SUGAR; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME REPLACEMENT; ENZYME STRUCTURE; ENZYME SYNTHESIS; FABRY DISEASE; FEMALE; GENE; GENE DELETION; GENE DISRUPTION; GENE OVEREXPRESSION; GLYCOPROTEIN SYNTHESIS; HOST CELL; KIDNEY; MALE; MNN4P GENE; MOUSE; NONHUMAN; OCH1 GENE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SINGLE DRUG DOSE; YEAST CELL;

ALPHA-GALACTOSIDASE; ANIMALS; FABRY DISEASE; FEMALE; HUMANS; KIDNEY; MALE; MICE; RECOMBINANT PROTEINS; YEASTS;

EID: 84863050085     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00248     Document Type: Article

References (45)

1. Spada M, et al. (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Gene. 79:31-40.
2. Hwu WL, et al. (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum. Mutat. 30:1397-1405.
3. Lin H Y, et al. (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ. Cardiovasc. Gene. 2:450-456.
4. Desnick RJ, Ioannou YA, Eng CM. (2001) Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. 8th ed. Scriver CR, Beaudet AL, Sly WS, Valle D (eds.). McGraw-Hill, New York, pp. 3733-3734.
5. Aerts JM, et al. (2008) Elevated globotriaosylsph-ingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 105:2812-2817.
6. Togawa T, et al. (2010) Plasma globotriaosylsph-ingosine as a biomarker of Fabry disease. Mol. Genet. Metab. 100:257-261.
7. Togawa T, et al. (2010) Tissue and plasma globo-triaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem. Biophys. Res. Commun. 399:716-720.
8. Schiffmann R, et al. (2000) Infusion of α-galactosi-dase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 97:365-370.
9. Eng CM, et al. (2001) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmaco-kinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68:711-722.
10. Eng CM, et al. (2001) Safety and efficacy of re-combinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345:9-16.
11. Kornfeld S, Sly WS. (2001) I-cell disease and pseudo-Hurler polydystrophy: disorders of lyso-somal enzyme phosphorylation and localization. In: The Metabolic and Molecular Bases of Inherited Disease. 8th ed. Scriver CR, Beaudet AL, Sly WS, Valle D (eds.). McGraw-Hill, New York, pp. 3469-3482.
12. Rosenfeld EL, Belenky DM, Bystrova NK. (1986) Interaction of hepatic asialoglycoprotein receptor with asialoorosomucoid and galactolyzed lysoso-mal alpha-glucosidase. Biochim. Biophys. Acta. 883:306-312.
13. Mehta A, et al. (2009) Fabry Outcome Survey investigators: enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet. 374:1986-1996.
14. Fervenza FC, Torra R, Warnock DG. (2008) Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics. 2:823-843.
15. Thurberg BL, et al. (2009) Cardiac microvascular pathology in Fabry disease: evaluation of en-domyocardial biopsies before and after enzyme replacement therapy. Circulation. 119:2561-2567.
16. Salviati A, Burlina A P, Borsini W. (2010) Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol. Sci. 31:299-306.
17. Sakuraba H, et al. (2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J. Hum. Genet. 51:180-8.
18. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. (2001) Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 68:14-25.
19. Chiba Y, et al. (2002) Production in yeast of α-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology. 12:821-828.
20. Sakuraba H, et al. (2006) Corrective effect on Fabry mice of yeast recombinant human α-galac-tosidase with N-linked sugar chains suitable for lysosomal delivery. Hum. Genet. 51:341-352.
21. Kuroda K, et al. (2006) Production of Man5GlcNAc2-type sugar chain by the methy-lotrophic yeast Ogataea minuta. FEMS Yeast Res. 6:1052-1062.
22. Odani T, Shimma Y, Tanaka A, Jigami Y. (1996) Cloning and analysis of the MNN4 gene required for phosphorylation of N-linked oligosaccharides in Saccharomyces cerevisiae. Glycobiology. 6:805-810.
23. Odani T, Shimma Y, Wang XH, Jigami Y. (1997) Mannosylphosphate transfer to cell wall mannan is regulated by the transcriptional level of the MNN4 gene in Saccharomyces cerevisiae. FEBS Lett. 420:186-190.
24. Ishii S, Kase R, Sakuraba H, Suzuki Y. (1993) Characterization of a mutant α-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem. Biophys. Res. Commun. 197:1585-1589.
25. Akeboshi H, et al. (2007) Production of recombi-nant β-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta. Appl. Environ. Microbiol. 73:4805-4812.
26. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. (1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin. Chim. Acta. 112:247-251.
27. Akeboshi H, et al. (2009) Production of human β-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogatae minuta MNN4 gene. Glycobiology. 19:1002-1009.
28. Ohshima T, et al. (1997) α-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 94:2540-2544.
29. Ohshima T, et al. (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. U. S. A. 96:6423-6427.
30. Kotani M, et al. (1994) Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine. Arch. Biochem. Biophys. 310:89-96.
31. Kawashima I, et al. (2006) Phospholipid storage in the myocardium of a unique Japanese case of idiopathic cardiomyopathy. Clin. Chim. Acta. 372:154-157.
32. Tajima Y, et al. (2009) Use of a modified α-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 85:569-580.
33. Zoon K. (2003) To manufacturers of biological products (Letter). Rockville, MD: U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research.
34. European Medicines Agency (EMEA). (2003) Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMEA/410/01). Revised. London, UK: EMEA.
35. Shibata N, Suzuki A, Kobayashi H, Okawa Y. (2007) Chemical structure of the cell-wall mannan of Candida albicans serotype A and its difference in yeast and hyphal forms. Biochem. J. 404:365-372.
36. Faille C, et al. (1990) Immunoreactivity of neogly-colipids constructed from oligomannosidic residues of the Candida albicans cell wall. Infect. Immun. 58:3537-3544.
37. Ballou CE. (1990) Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects. Methods Enzymol. 185:440-470.
38. Vedder AC, et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsi-dase alfa or beta at a dose of 0.2 mg/kg. PLoS One. 2:e598.
39. Vedder AC, et al. (2008) Treatment of Fabry disease with different dosing regimens of agalsi-dase: effects on antibody formation and GL-3. Mol. Genet. Metab. 94:319-325.
40. Lee K, et al. (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 13:305-313.
41. Sly WS, et al. (2006) Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc. Natl. Acad. Sci. U. S. A. 103:15172-15177.
42. Takamatsu S, et al. (2004) Monitoring of the tissue distribution of fibroblast growth factor containing a high mannose-type sugar chain produced in mutant yeast. Glycoconj. J. 20:385-397.
43. Zhu Y, et al. (2009) Glycoengineered acid α-glu-cosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17:954-963.
44. Zhou Q, et al. (2011) Strategies for neoglycan conjugation to human acid α-glucosidase. Bioconjug. Chem. 22:741-751.
45. Tsuji D, et al. (2011) Highly phosphomannosy-lated enzyme replacement therapy for GM2 gan-gliosidosis. Ann. Neurol. 69:691-701.